Efficacy and Safety of Endothelin Receptor Antagonists Combined with Sodium–Glucose Cotransporter-2 Inhibitors Versus Monotherapy in Proteinuric Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine · 14.11.2026 · 15 (22) · 8931
DOI: 10.3390/jcm15228931 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.11.2026. Verfasst von Saud Aljohani und 8 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Endothelin receptor antagonists (ERAs) lower albuminuria in chronic kidney disease (CKD) but cause dose-dependent fluid retention, which natriuretic sodium–glucose cotransporter-2 inhibitors (SGLT2is) may offset. We compared ERA plus SGLT2i therapy with either class alone in adults with proteinuric CKD.
Methods
PubMed/MEDLINE, Web of Science and CENTRAL were searched up to 26 September 2026, with citation searching and a supplementary PubMed search on 5 November 2026 (PROSPERO CRD420261340145). Proteinuria was pooled as ratios of geometric means (random effects) and adverse events as Mantel–Haenszel risk ratios (RRs); risk of bias was assessed with RoB 2 and ROBINS-I, and certainty with GRADE.
Results
Nine studies (seven randomized; 1043 participants) were included. Compared with an SGLT2i alone, adding an ERA lowered albuminuria or proteinuria by a further 29.8% (ratio of geometric means 0.70; 95% CI 20.4–38.1%; six trials, 509 participants; I2 = 0%; moderate certainty, surrogate outcome). Fluid-retention events were numerically more frequent with the combination (RR 1.69, 0.91–3.16; low certainty) and more frequent with higher-dose zibotentan (RR 2.33, 1.29–4.20; moderate certainty); peripheral edema and discontinuation estimates were model-dependent. Compared with an ERA alone, the combination reduced fluid-retention events (RR 0.38, 0.20–0.72; low certainty). In one exploratory 64-participant stratum, eGFR declined more slowly with atrasentan over 2.5 years (very low certainty).
Conclusions
Adding an ERA to an SGLT2i lowers albuminuria or proteinuria, a surrogate outcome, by about 30%, and SGLT2i co-therapy may reduce ERA-related fluid retention; safety evidence is short-term and excludes heart failure, so trials with kidney and heart-failure outcomes are needed.
Zitieren
APA
Aljohani, S., Alarwi, O., Aljohani, T., Alharbi, A., AlAbbasi, Y., Aloufi, S., AlAhmadi, H., Almadani, M., & Alshammari, O. (2026). Efficacy and Safety of Endothelin Receptor Antagonists Combined with Sodium–Glucose Cotransporter-2 Inhibitors Versus Monotherapy in Proteinuric Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 15(22), 8931. https://doi.org/10.3390/jcm15228931
Vancouver
Aljohani S, Alarwi O, Aljohani T, Alharbi A, AlAbbasi Y, Aloufi S, et al. Efficacy and Safety of Endothelin Receptor Antagonists Combined with Sodium–Glucose Cotransporter-2 Inhibitors Versus Monotherapy in Proteinuric Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026;15(22):8931. doi:10.3390/jcm15228931
BibTeX
@article{Aljohani2026,
author = {Aljohani, Saud and Alarwi, Osama and Aljohani, Thabat and Alharbi, Abdullah and AlAbbasi, Yusra and Aloufi, Shahad and AlAhmadi, Hazim and Almadani, Mujtaba and Alshammari, Omar},
title = {Efficacy and Safety of Endothelin Receptor Antagonists Combined with Sodium–Glucose Cotransporter-2 Inhibitors Versus Monotherapy in Proteinuric Chronic Kidney Disease: A Systematic Review and Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {22},
pages = {8931},
doi = {10.3390/jcm15228931}
}
EUVIMED